Dermatol. praxi. 2017;11(2):55-57 | DOI: 10.36290/der.2017.012

Advances in biological therapy for psoriasis

MUDr. Alena Machovcová, Ph.D., MBA
Dermatovenerologické oddělení FN v Motole, Praha, Klinika nemocí z povolání UK 1. LF a VFN, Praha

In spite of indisputable progress achieved in treating this condition, psoriasis still remains an incurable disease. Biological therapy

has brought a revolution in the treatment of psoriasis. Clinical trials are still being carried out and new treatment options for

severe psoriasis and psoriatic arthritis are emerging. Recently, anti-interleukin 17 antibodies have begun to be used in treating

psoriasis and psoriatic arthritis.

Keywords: plaque psoriasis, biological therapy for psoriasis, interleukin 17, anti-IL 17 antibodies

Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machovcová A. Advances in biological therapy for psoriasis. Dermatol. praxi. 2017;11(2):55-57. doi: 10.36290/der.2017.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Prey S, Pau C, Bronsard V, et al. (2010), Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. JEADV 2010; 24(Suppl.2): 31-35. Go to original source... Go to PubMed...
    2. Villani AP, Rouzaud M, Sevrain M, et al. Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. JEADV 2014; 28(Suppl.5): 27-32. Go to original source... Go to PubMed...
    3. L?nnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014; 7: 251-259. Go to original source... Go to PubMed...
    4. Cetkovská P, Kojanová M. Česká doporučení k biologické léčbě závažné chronické ložiskové psoriázy. Čes-slov Derm, 2012; 87(1): 1-76.
    5. Horreau C, Pouplard C, Brenaut E et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. JEADV 2013; 27(Suppl. 3): 12-29. Go to original source... Go to PubMed...
    6. Machado-Pinto JM, Diniz MS, Bavoso NC. Psoriasis: new comorbidities. An Bras Dermatol 2016; 91(1): 8-16. Go to original source... Go to PubMed...
    7. Nast A, Boehncke WH, Mrowietz U et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG 2012; 10: S1-S95. Go to original source... Go to PubMed...
    8. Bachelez H. Interleukin-17 inhibition: a route to psoriasis clearance? Lancet 2015; 386: 510-512. Go to original source... Go to PubMed...
    9. Paul C, Gourraud PA, Bronsard V et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. JEADV 2010; 24: 2-9. Go to original source... Go to PubMed...
    10. Machovcová A. Konvenční systémová léčba chronické plakové psoriázy v éře biologik. Dermatol. praxi 2013; 7(4): 152-155.
    11. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2011); 303(1): 1-10. Go to original source... Go to PubMed...
    12. Arenberger P, Cetkovská P, Kojanová M. Biologická léčba psoriázy. Acta medicinae 2012; 4(1): 44-49.
    13. Lebwohl M. Do we need more psoriasis therapies? Lancet 2015; 386: 512-514. Go to original source... Go to PubMed...
    14. Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatol Treat 2015; 26(1): 41-44. Go to original source... Go to PubMed...
    15. Lynde CW, Poulin Y, Vender R et al. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. JAAD 2014; 71: 141-150. Go to original source... Go to PubMed...
    16. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-724. Go to original source... Go to PubMed...
    17. Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther 2016; 6(1): 25-37. Go to original source... Go to PubMed...
    18. Papp KA, Leonardi C, Menter A, et al. Brodalumab, anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189. Go to original source... Go to PubMed...
    19. Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17a monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71: 1176-1182. Go to original source... Go to PubMed...
    20. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211. Go to original source... Go to PubMed...
    21. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194. Go to original source... Go to PubMed...
    22. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-4741. Go to original source... Go to PubMed...
    23. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-1383. Go to original source... Go to PubMed...
    24. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-338. Go to original source... Go to PubMed...
    25. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015: 73: 400-409. Go to original source... Go to PubMed...
    26. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-551. Go to original source... Go to PubMed...
    27. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2016 Sep 20, pii: S0190-9622(16)30624-7. doi: 10.1016/j.jaad.2016.08.008. [Epub ahead of print]. Go to original source... Go to PubMed...
    28. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis N Engl J Med. 2016; 375(4): 345-356. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.